TimesSquare Capital Management LLC Has $13.32 Million Holdings in CG Oncology, Inc. $CGON

TimesSquare Capital Management LLC reduced its stake in shares of CG Oncology, Inc. (NASDAQ:CGON) by 1.0% in the second quarter, according to its most recent filing with the SEC. The institutional investor owned 512,201 shares of the company’s stock after selling 5,057 shares during the period. TimesSquare Capital Management LLC owned about 0.67% of CG Oncology worth $13,317,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also bought and sold shares of the company. Mirae Asset Global Investments Co. Ltd. grew its stake in shares of CG Oncology by 15.6% in the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,945 shares of the company’s stock worth $77,000 after acquiring an additional 398 shares in the last quarter. Invesco Ltd. increased its stake in CG Oncology by 2.5% in the 1st quarter. Invesco Ltd. now owns 27,754 shares of the company’s stock valued at $680,000 after buying an additional 685 shares during the last quarter. Massachusetts Financial Services Co. MA boosted its stake in shares of CG Oncology by 0.4% in the 1st quarter. Massachusetts Financial Services Co. MA now owns 258,090 shares of the company’s stock worth $6,321,000 after buying an additional 933 shares during the last quarter. Winthrop Capital Management LLC purchased a new position in shares of CG Oncology in the 2nd quarter worth approximately $38,000. Finally, Swiss National Bank increased its position in shares of CG Oncology by 1.9% during the first quarter. Swiss National Bank now owns 81,100 shares of the company’s stock valued at $1,986,000 after acquiring an additional 1,500 shares during the last quarter. 26.56% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of research analysts have issued reports on CGON shares. Guggenheim initiated coverage on CG Oncology in a research note on Tuesday, October 7th. They issued a “buy” rating and a $90.00 price objective for the company. Zacks Research upgraded shares of CG Oncology from a “strong sell” rating to a “hold” rating in a research report on Monday, September 1st. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $75.00 price objective on shares of CG Oncology in a research report on Monday, September 8th. Jones Trading started coverage on shares of CG Oncology in a research report on Monday, September 8th. They set a “buy” rating and a $50.00 target price for the company. Finally, JPMorgan Chase & Co. lifted their price target on shares of CG Oncology from $41.00 to $47.00 and gave the stock an “overweight” rating in a report on Friday, September 26th. One equities research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, CG Oncology currently has an average rating of “Moderate Buy” and a consensus target price of $58.70.

CG Oncology Trading Up 1.5%

Shares of NASDAQ:CGON opened at $39.41 on Thursday. The company has a 50 day moving average of $39.25 and a 200 day moving average of $30.70. The stock has a market cap of $3.01 billion, a P/E ratio of -22.27 and a beta of 1.32. CG Oncology, Inc. has a 12 month low of $14.80 and a 12 month high of $45.56.

Insiders Place Their Bets

In related news, Director Leonard E. Post sold 5,000 shares of the company’s stock in a transaction on Tuesday, September 30th. The shares were sold at an average price of $40.09, for a total value of $200,450.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Hong Fang Song sold 100,000 shares of the company’s stock in a transaction dated Wednesday, September 3rd. The shares were sold at an average price of $27.80, for a total transaction of $2,780,000.00. Following the sale, the director owned 2,903,931 shares of the company’s stock, valued at approximately $80,729,281.80. The trade was a 3.33% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders have sold 174,359 shares of company stock worth $5,511,784. 7.40% of the stock is currently owned by corporate insiders.

CG Oncology Profile

CG Oncology, Inc, an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients.